Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W N Deininger

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
Haematologica|February 3, 2004
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapyThoralf Lange, Thomas Bumm, Sandra Otto, et al.
Blood|October 31, 2002
High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CMLThoralf Lange, Christine Günther, Thomas Köhler, et al.
Oncogene|December 5, 2003
c-CBL is not required for leukemia induction by Bcr-Abl in miceDaniela M Dinulescu, Lisa J Wood, Lei Shen, et al.
Cancer Research|September 3, 2010
A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitorsJi-Heui Seo, Lisa J Wood, Anupriya Agarwal, et al.
Haematologica|September 17, 2016
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosisVikas Gupta, Ruben A Mesa, Michael W N Deininger, et al.
Blood|August 12, 2004
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970Amie S Corbin, Ian J Griswold, Paul La Rosée, et al.
Cancer Research|December 6, 2006
Characterization of murine JAK2V617F-positive myeloproliferative diseaseThomas G P Bumm, Collin Elsea, Amie S Corbin, et al.
Cancer Research|January 7, 2006
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignanciesMarcus M Schittenhelm, Sharon Shiraga, Arin Schroeder, et al.
Blood|November 2, 2002
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majorityThomas Bumm, Christel Müller, Haifa-Kathrin Al-Ali, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
Haematologica|February 3, 2004
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapyThoralf Lange, Thomas Bumm, Sandra Otto, et al.
Blood|October 31, 2002
High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CMLThoralf Lange, Christine Günther, Thomas Köhler, et al.
Oncogene|December 5, 2003
c-CBL is not required for leukemia induction by Bcr-Abl in miceDaniela M Dinulescu, Lisa J Wood, Lei Shen, et al.
Cancer Research|September 3, 2010
A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitorsJi-Heui Seo, Lisa J Wood, Anupriya Agarwal, et al.
Haematologica|September 17, 2016
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosisVikas Gupta, Ruben A Mesa, Michael W N Deininger, et al.
Blood|August 12, 2004
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970Amie S Corbin, Ian J Griswold, Paul La Rosée, et al.
Cancer Research|December 6, 2006
Characterization of murine JAK2V617F-positive myeloproliferative diseaseThomas G P Bumm, Collin Elsea, Amie S Corbin, et al.
Cancer Research|January 7, 2006
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignanciesMarcus M Schittenhelm, Sharon Shiraga, Arin Schroeder, et al.
Blood|November 2, 2002
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majorityThomas Bumm, Christel Müller, Haifa-Kathrin Al-Ali, et al.
Pageof 6